Understanding the Class Action Lawsuit Against Allarity Therapeutics
Glancy Prongay & Murray LLP is actively working to defend the rights of investors in Allarity Therapeutics, Inc. This well-respected national law firm, known for safeguarding shareholder rights, has launched a class action lawsuit on behalf of those who purchased Allarity securities. The period relevant to this lawsuit is from May 17, 2022, to July 19, 2024, which is referred to as the 'Class Period'.
Class Action Filing Details
The main goal of the class action is to address the concerns of investors who bought shares of Allarity Therapeutics, Inc. (NASDAQ: ALLR) and experienced financial losses as a result. Investors have until November 12, 2024, to submit a lead plaintiff motion, giving affected individuals a chance to seek legal recourse.
Filing Criteria
If you suspect you faced financial losses during the Class Period, it might be helpful to get in touch with GPM. Be sure to provide your contact information to open a conversation about potential claims under federal securities laws.
Allegations in the Class Action
This lawsuit emerged after Allarity announced in early 2023 that the SEC was investigating it regarding disclosures linked to the FDA and its NDA for Dovitinib. This news led to a significant drop in Allarity's stock price, highlighting how such information can severely affect investor confidence.
Recent Corporate Developments
In December 2023, Allarity faced further difficulties when it announced the firing of its CEO, causing additional declines in stock price. Further challenges emerged in July 2024 when the company revealed it had received a Wells Notice from the SEC, exacerbating the situation and leading to even steeper drops in stock valuation.
Claims of Misinformation
The class action complaint claims that during the Class Period, the company’s executives did not disclose key information about the regulatory outlook for Dovitinib. The allegations include mismanagement and inappropriate conduct regarding the drug's approval, which misled investors about the company's true standing. These claims suggest that this lack of transparency made the company subject to increased regulatory oversight and potential legal issues.
Impact on Investors
In light of these allegations, many investors have experienced a drastic decline in the value of their investments, prompting GPM to advocate for their rights. By highlighting these issues, the firm seeks to empower shareholders who feel misled by the company’s lack of transparency during such a crucial time.
Pursuing Justice for Shareholders
All affected investors are urged to consider taking legal action by the deadline to ensure their positions as lead plaintiffs. For more information, interested individuals can contact Charles H. Linehan, an attorney at GPM, who can provide guidance regarding their legal rights in this situation.
Contact Information
Investors looking for more details can reach out to GPM at 310-201-9150 or Toll-Free at 888-773-9224. You can also send email inquiries to shareholders@glancylaw.com. When contacting the firm, please include important details such as your mailing address and the number of shares purchased.
Frequently Asked Questions
What is the purpose of the class action lawsuit against Allarity Therapeutics?
This class action lawsuit seeks justice for investors who faced losses due to misleading statements and regulatory issues related to Allarity's operations.
Who can join this class action lawsuit?
Any investor who purchased securities of Allarity Therapeutics, Inc. (ALLR) during the Class Period is eligible to join the lawsuit.
What are the important dates for this lawsuit?
It's essential for investors to remember that the deadline for filing a lead plaintiff motion is November 12, 2024.
How can one file a claim in this class action?
To file a claim, investors should contact Glancy Prongay & Murray LLP with their information and express their desire to join the lawsuit.
What steps should I take if I think I have a claim?
If you believe you've experienced losses, it's a good idea to reach out to legal counsel to discuss your options under federal securities laws.
